logo
Plus   Neg
Share
Email

Neurocrine Biosciences, Idorsia Amend Option Agreement To License ACT-709478

Neurocrine Biosciences, Inc. (NBIX) and Idorsia Ltd. have amended their 2019 agreement granting Neurocrine Biosciences an option to license ACT-709478, a potent brain penetrating T-type calcium channel blocker in development for epilepsy.

Upon Investigational New Drug application acceptance by the FDA, expected in mid-2020, Neurocrine Biosciences will have 30 days to exercise the option to license ACT-709478. If the option is exercised by Neurocrine Biosciences, Idorsia will receive an upfront payment of $45 million. Idorsia may also receive up to $365 million in additional development and regulatory milestone payments.

Also, Neurocrine Biosciences will provide an incremental $7 million in funding to Idorsia as part of the research collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney Co.'s (DIS) streaming service Disney+ will be launched on March 24 in the UK and other markets in the Western Europe, one week earlier than originally planned on March 31. Pricing also been confirmed at 5.99 pounds/6.99 euros per month or 59.99 pounds/69.99 euros for an annual subscription.... Facebook plans to add 1,000 new jobs in the UK this year, with more than half of this focused on technology. The new jobs come ahead of Facebook's planned opening of its new office premises in King's Cross, London next year. It will take the social media giant's total employee count in the UK to more than 4,000 by the end of this year. E-commerce giant Amazon is planning to add 10,000 electric vehicles or EVs to its delivery fleet in India by 2025, as part of its efforts to combat the severe climate change. These vehicles are in addition to Amazon's plan of adding 100,000 electric vehicles in its global delivery fleet by 2030, as per the Climate Pledge, which it co-founded and signed in September 2019.
Follow RTT
>